Notably, monoclonal antibodies targeting immune checkpoints such as programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown efficacy in melanoma, non‐small cell lung cancer, renal cell carcinoma, as well as gastrointestinal malignancy.7 The gene discussed is CD274; the disease is melanoma.